AI
ELTX icon

Arena Investors’s Elicio Therapeutics ELTX Stock Holding History

Arena Investors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$206K Buy
+50,000
New +$423K 1.64% 8

Other funds holding ELTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MHC
Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Arena Investors's ELTX Position: Q2 2024 in Review

Arena Investors opened a new position in Elicio Therapeutics (ELTX) in Q2 2024: 50,000 shares worth $206K. The stake represents 1.64% of the portfolio and ranks #8 among its holdings.

20 funds tracked by Wall St. Rank hold ELTX as of Q2 2024.

  • Arena Investors held 50,000 shares of Elicio Therapeutics worth $206K as of Q2 2024.
  • Elicio Therapeutics was a new Arena Investors position in Q2 2024.
  • Elicio Therapeutics made up 1.64% of Arena Investors's portfolio in Q2 2024, its #8 holding.
  • 20 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2024.

Based on Arena Investors's 13F filing for Q2 2024, filed 14 Aug 2024.